- In January 2025, Phillips Medisize, a subsidiary of Molex, completed the acquisition of Vectura Group Ltd., enhancing its capabilities in inhalation drug delivery. This strategic move integrates Vectura's expertise in dry powder inhalers, metered dose inhalers, nebulizers, and nasal inhalers, including proprietary platforms such as the Gyrohaler and FOX devices. The acquisition also brings Vectura's strengths in pharmaceutical analysis, process development, and regulatory services, bolstering Phillips Medisize's end-to-end development and manufacturing services. By adding approximately 350 employees to its global team, Phillips Medisize aims to meet the growing global demand for innovative therapies targeting chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), as well as non-respiratory conditions
- In January 2025, Nipro PharmaPackaging (Japan) and Nemera (France) successfully completed compatibility testing between Nemera’s UniSpray and Nipro’s unit-dose microvials. This collaboration aims to accelerate the time to market for combination products, particularly those used for rescue and crisis intervention. The rigorous testing confirmed that the combination product meets required dose delivery and reliability standards, ensuring its safety and performance. This development enhances the reliability of systemic drug administration via nasal delivery, benefiting patients requiring rapid treatment in emergency situations. The impact on the market includes the introduction of a reliable and efficient drug delivery system, potentially improving patient outcomes in critical care scenarios
